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Abstract
Background: Intravenous morphine use is associated with elevated histamine release leading to
bronchoconstriction, edema and hemodynamic instability in some patients. This study evaluated
the possibility that sulfite, which is present as a preservative in many morphine preparations, might
contribute to histamine release in vitro.
Results: The human mast cell line, HMC-1, was exposed to various morphine concentrations, in
the absence of sulfite, under cell culture conditions. Clinically attained concentrations of morphine
(0.018µg/ml and 0.45µg/ml) did not cause increased histamine release from mast cells. There was
a significant increase in histamine release when the morphine concentration was increased by 1184-
fold (668µg/ml morphine). Histamine release from mast cells exposed to morphine and/or sulfite
required the presence of prostaglandin H synthetase. Histamine release in experiments using
sulfite-containing morphine solutions was not statistically different from that observed in
morphine-only solutions.
Conclusion: Sulfite in sulfite-containing morphine solutions, at concentrations seen clinically, is
not responsible for histamine release in in vitro experiments of the human mast cell line, HMC-1.
This does not preclude the fact that sulfite may lead to elevation of histamine levels in vivo.
Background
Morphine is among the most common analgesic agents
used in the intensive care setting. It is usually adminis-
tered parenterally as an intravenous infusion. Despite its
efficacy, its use is associated with a number of hazards
including respiratory depression [1], tolerance [2], physi-
ological dependence [2] and abstinence upon discontinu-
ation of treatment [2]. Less frequent, but perhaps more
profound, is the bronchoconstriction, edema and hemo-
dynamic instability seen in some patients following intra-
venous bolus doses of the drug [3-7]. These effects have
been attributed to histamine release from mast cells by
morphine [3-7].
A number of clinical studies have demonstrated an
increase in plasma histamine concentration following
intravenous morphine administration [3-7], but these
studies generally fail to provide details concerning the for-
mulation of the morphine employed. Most of the mor-
phine used in both clinical practice and for clinical
investigations contains sodium bisulfite as a preservative
[8]. Until the mid 1980's sulfite preservatives were gener-
ally considered universally safe; however, their status was
changed after the receipt by the FDA of more than 250
reports of serious and life-threatening reactions related to
sulfite exposure through both diet and therapeutic agents
[9,10].
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In the body, sulfites are generally oxidized by the mito-
chondrial enzyme sulfite oxidase and non-toxic metabo-
lites are excreted in the urine [11]. A small amount of the
sulfite, either ingested or injected may also be metaboli-
cally activated by a number of other enzyme systems
including xanthine oxidase [12], peroxidase [11] and
prostaglandin H synthetase [13]. As an electron acceptor
in these reactions or through electron transfer from tran-
sition metals such as copper and iron, sulfite may accept
an electron from the resulting hydroxyl, superoxide or sul-
fate radicals [14] leading to the formation of sulfite
radical.
Sulfite radicals are chemically reactive and have been
implicated in lipid [15], protein [16] and nucleic acid [17]
oxidation as well as neuronal injury [18]. They may stim-
ulate neutrophils to release oxygen free radicals and aug-
ment the free radical response to other neutrophil
activators [19]. In addition, their generation has been
shown to contribute to oxidative stress resulting in sulfite
toxicity and impaired B-cell function.
The potential generation of free radicals from sulfite pre-
servatives may confound our understanding the associa-
tion of morphine with histamine release in man. A
number of studies have demonstrated that, when exposed
to free radicals, mast cells may release histamine [20-26].
It is possible; therefore, that the histamine released fol-
lowing morphine infusion may be the result of the forma-
tion of sulfite radicals from the preservative rather than
the morphine itself. This study evaluated the possibility
that sulfite and its activation might contribute to hista-
mine release by mast cells in vitro.
Results
Mast cell histamine release
Total histamine content of mast cells was calculated by
freezing and thawing suspensions for 3 cycles. Cell sus-
pensions containing 500,000 cells/ml released 1.27µg/ml
(0.21) histamine, corresponding to 2.53 pg (0.41) hista-
mine per mast cell.
Mast cells stimulated with 0.25µg/ml calcium ionophore
released 63% (7.2) of total histamine.
Effect of sulfite-free morphine concentration on histamine 
release
The effect of histamine release from mast cells treated with
both clinically attained concentrations of morphine and
concentrations above those seen clinically was
determined.
To chemically defined reaction mixtures, morphine was
added at varying concentrations (18 ng/ml, 450 ng/ml,
6.68µg/ml and 668µg/ml). Enzymes causing free radical
activation were not present. The blank sample contained
no morphine. Reaction mixtures were incubated in a
water bath at 37°C for 60 minutes. Experiments were per-
formed in triplicate. Histamine release from samples was
determined following derivitization with o-phthaldialde-
hyde and mercaptoethanol using high-performance liq-
uid chromatography as detailed below. Histamine release
from reaction mixtures was expressed as a % of total his-
tamine present in the cell pellet.
Histamine release from reaction mixtures containing mor-
phine at all concentrations was not statistically different
(p > 0.1) from histamine release from blank samples
(Table 1).
To verify the time dependence of histamine release, a mor-
phine concentration of 668 µg/ml was tested. Release was
detectable as early as 5 minutes after the addition of drug
and appeared to plateau between 40 and 60 minutes (Fig-
ure 1).
Effect of sulfite-containing morphine solutions on 
histamine release
To determine whether the addition of sodium bisulfite
causes increased histamine release from mast cells,
sodium bisulfite at a concentration of 0.1% of morphine
concentration (the % of sulfite present in morphine most
formulations) was added to the reaction mixtures
described previously. Blank samples contained neither
morphine nor sulfite. Specimens were incubated, dried,
re-dissolved, derivitized and analyzed as above.
There was no statistical difference in histamine release at
any concentration of morphine with sulfite compared
with blank samples (Table 1).
Reaction mixtures containing 668µg/ml morphine with
0.1% sodium bisulfite were incubated for 5, 10, 20, 40
and 60 minutes yielded results identical to those observed
in the absence of sodium bisulfite (results not shown).
Effect of prostaglandin H synthetase on histamine release 
from mast cell reaction mixtures
Prostaglandin H synthestase may catalyze free radical for-
mation [20]. The first experiment investigated its effect on
mast cell histamine release in the absence of sulfite and
morphine. This ensured that any increase in histamine
release in subsequent experiments was not due to the
effect of the enzyme only.
Prostaglandin H synthetase was added to reaction mix-
tures at a concentration of 25 mU. In reaction mixtures
containing no drug, the enzyme was added to mast cell
samples containing neither morphine nor sulfite. Con-
trols contained no enzyme.BMC Pharmacology 2004, 4:21 http://www.biomedcentral.com/1471-2210/4/21
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Reaction mixtures containing the enzyme alone (no
sulfite or morphine) produced similar histamine release
compared to blank samples (3.2% (0.7) of total and 2.9%
(2.6) of total respectively). The presence of prostaglandin
H synthetase had no effect.
The effect of clinically attained concentrations of mor-
phine in the presence of prostaglandin H synthetase on
mast cell histamine release was investigated. In vivo stud-
ies show histamine release at these concentrations of mor-
phine [3-7]. Morphine sulfate was added to the mast cell
solution at clinically attained concentrations of 450 ng/ml
(a typical peak in vivo concentration following an intrave-
nous morphine bolus) and 18 ng/ml (a typical steady-
state concentration during a 20 µg/kg/hour morphine
infusion) [27]. Mast cell histamine release from higher
concentrations of morphine (668µg/ml and 6.68µg/ml)
was also investigated.
Blank samples contained water instead of morphine. All
samples contained 25 mU of prostaglandin H synthetase.
Specimens were incubated, dried, re-dissolved, derivitized
and analyzed as described below. Histamine release val-
ues are shown in Table 2. There was no statistical differ-
ence between histamine release from morphine samples
at both clinically-attained concentrations (18 ng/ml (p =
0.87) and 450 ng/ml (p = 0.08)) and histamine release
from blank samples. Histamine release from HMC-1 cells
incubated with morphine 668µg/ml and 6.68µg/ml were
significantly increased compared with blank samples (p =
0.03 at both concentrations). Results are shown in table 2.
Maximum histamine release (16.1% of total (6.3))
occurred at the highest concentration of morphine
(668µg/ml) (Figure 1).
The effect of sodium bisulfite 0.1% in varying concentra-
tions of morphine in the presence of prostaglandin H syn-
Concentration-effect of morphine in the presence of prostaglandin Hsynthetase on histamine release from the mast cell line  HMC-1 (mean of 3 experiments) Figure 1
Concentration-effect of morphine in the presence of prostaglandin Hsynthetase on histamine release from the mast cell line 
HMC-1 (mean of 3 experiments).
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thetase was investigated. This preservative is present in
many morphine preparations and its effect on histamine
release from mast cells is determined here. Morphine was
added to the mast cell samples at concentrations of
668µg/ml, 6.68µg/ml, 450 ng/ml and 18 ng/ml. Sodium
bisulfite was added to samples at a concentration of 0.1%
of morphine concentration. Controls contained mor-
phine only. Each sample also contained 25 mU of pros-
taglandin H synthetase. Specimens were incubated, dried,
re-dissolved, derivitized and analyzed as described below.
Reaction mixtures containing morphine 668µg/ml with
0.1% sodium bisulfite showed a statistically significant
increase in histamine release compared with blank sam-
ples (p = 0.03). There was no statistical difference in his-
tamine release between morphine only samples at all
concentrations and samples containing morphine and
0.1% sodium bisulfite (Table 2) (morphine 668µg/ml (p
= 0.8), morphine 6.68µg/ml (p = 0.13), morphine 450
ng/ml (p = 0.89) and morphine 18 ng/ml (p = 0.56).
Sulfite did not have any additive effect on histamine
release from mast cells in the presence of morphine and
prostaglandin H synthetase.
Studies looking at plasma histamine levels following mor-
phine administration in humans have shown peak hista-
mine levels within 5 minutes of administration [3,4,6].
This experiment investigated whether maximum hista-
mine release occurred at a similar time in vitro in the pres-
ence of the enzyme prostaglandin H synthetase. HMC-1
cells were incubated at 37°C for 5, 10, 20, 30 and 60 min-
utes with morphine 668µg/ml, 0.1% sodium bisulfite and
25 mU prostaglandin H synthetase. The cells were centri-
fuged and the supernatant was examined for the presence
of histamine and expressed as a % of total histamine.
Histamine release was time dependent with a maximum
effect after 1 hour of incubation (Figure 2).
Interestingly, reaction mixtures containing a typical peak
morphine concentration (450 ng/ml) showed a
significant increase in histamine release in the presence of
prostaglandin H synthetase compared with no enzyme.
This was true for both sulfite-free (p = 0.003) and sulfite-
containing (p = 0.009) morphine solutions. This suggests
that even at clinically-attained morphine concentrations,
it is not only possible to cause the metabolic activation of
sulfite, but also that of morphine.
The effect of sulfite alone (without morphine) on hista-
mine release from mast cells was investigated. To 4 mast
Table 1: Histamine release from HMC-1 cells stimulated with varying concentrations of morphine with and without sulfite Histamine 
release expressed as a percentage of release of histamine in comparison to control (SD). As a control, the HMC-1 cells were allowed to 
freeze and thaw for 3 cycles to release the remaining histamine from cells. Each value represents the mean (SD) of triplicate 
determinations.
Morphine concentration (µg/ml) Histamine release (% total)* Sodium bisulfite
+-
0 2.9 (2.6)
0.018 2.5 (0.75) 3.2 (1.1)
0.450 1.7 (0.4) 2.6 (0.4)
6.68 1.8 (0.6) 2.2 (1.3)
668 2.1 (0.06) 2.8 (0.2)
Table 2: Histamine release from HMC-1 cells stimulated with varying concentrations of morphine with and without sulfite in the 
presence of prostaglandin H synthetase. Histamine release expressed as a percentage of release of histamine in comparison to control 
(SD). As a control, the HMC-1 cells were allowed to freeze and thaw for 3 cycles to release the remaining histamine from cells. Each 
value represents the mean (SD) of triplicate determinations.
Morphine concentration (µg/ml) Histamine release (% total)* Sodium bisulfite
+-
0 2.9 (2.6)
0.018 3.3 (2.9) 4.5 (1.4)
0.450 6.5 (0.9) 6.7 (1.8)
6.68 8 (0.3) 6.2 (1.5)
668 17.6 (7.8) 16.1 (6.3)BMC Pharmacology 2004, 4:21 http://www.biomedcentral.com/1471-2210/4/21
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cell reaction mixtures, varying concentrations of sulfite
(0.018 ng/ml, 0.45 ng/ml, 0.007µg/ml and 0.67µg/ml)
were added. These concentrations of sulfite correspond to
the concentration of sulfite present in morphine solutions
of 18 ng/ml, 450 ng/ml, 6.6µg/ml and 668µg/ml. To each
sample 25 mU prostaglandin H synthetase was added.
The highest concentration of sulfite (0.67µg/ml) was
incubated for 10, 20, 40 and 60 minutes to assess time
dependence. The reaction mixtures were incubated, cen-
trifuged and analyzed as described below.
In the presence of prostaglandin H synthetase, sulfite
resulted in histamine release from mast cells. There was a
significant increase in histamine release (9.7% (0.65) of
total) in the reaction mixture containing 0.67µg/ml sulfite
(p = 0.01). There was no statistically significant difference
in histamine release compared with blank samples at all
other concentrations of sulfite (0.018 ng/ml sulfite (2.8%
(0.3) of total, p = 0.91), 0.45 ng/ml sulfite (1.93% (0.35)
of total, p = 0.53) and 0.007µg/ml sulfite (4.5% (0.7) of
total, p = 0.36) (Table 3).
Time response effects of morphine 668 µg/ml in the presence of 0.1% Na bisulfite and 25 mU prostaglandin H synthetase on  histamine release in HMC-1 cells (mean of 3 experiments) Figure 2
Time response effects of morphine 668 µg/ml in the presence of 0.1% Na bisulfite and 25 mU prostaglandin H synthetase on 
histamine release in HMC-1 cells (mean of 3 experiments).
Table 3: Histamine release from HMC-1 cells stimulated with varying concentrations of sulfite-only solutions in the presence of 
prostaglandin H synthetase. Histamine release expressed as a percentage of release of histamine in comparison to control (SD). As a 
control, the HMC-1 cells were allowed to freeze and thaw for 3 cycles to release the remaining histamine from cells. Each value 
represents the mean (SD) of triplicate determinations.
Sulfite concentration (ng/ml) Histamine release (% total)
0.018 2.8 (0.3)
0.45 1.93 (0.35)
7 4.5 (0.7)
670 9.7 (0.65)
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The time-dependent experiment showed histamine
release of 8% of total (3.3) at 10 minutes incubation,
7.7% of total (2.2) at 20 minutes, 10.5% of total (6.1) at
40 minutes and 9.7% of total (0.65) at 60 minutes.
Discussion
Our experiments showed similar histamine release from
the mast cell line HMC-1 stimulated with morphine with
or without 0.1% sodium bisulfite. Maximum histamine
release was 16.1% of total in morphine only samples and
17.6% of total in morphine with 0.1% sodium bisulfite
samples. This percentage is similar to other studies of his-
tamine release in the human mast cell line HMC-1, where
maximum release was 20–30% [28-30]. In our study, the
concentrations of morphine and sulfite required to
achieve maximum histamine release were significantly
higher than concentrations seen clinically. Reaction mix-
tures containing sulfite only also caused significant hista-
mine release at high concentrations. Blank samples,
containing neither morphine nor sulfite, did not cause a
significant increase in histamine release (Table 2). These
results suggest that at high concentrations, both sulfite
and morphine could be responsible for elevated hista-
mine release from mast cells. In addition to the formation
of the sulfite radical from sulfite, it is possible that carbon-
centered or nitrogen-centered free radicals are being gen-
erated from the metabolic activation of morphine [20],
thereby inducing mast cell histamine release.
HMC-1 cells contain histamine and release their hista-
mine content in response to various exogenous stimuli
[28-30]. Our study showed no evidence of elevated hista-
mine release from mast cells when stimulated with mor-
phine and/or sulfite at concentrations seen clinically
(both peak and steady-state). Although HMC-1 exhibits a
phenotype similar to that of human mast cells [31], it is
possible that immature cells (cell lines) are less sensitive
than mature (primary) cells [28]. The model used is an
artificial system and may not represent physiological con-
ditions. In addition, maximum histamine release
occurred after a one hour incubation. This is significantly
different from the in vivo situation, where maximum
release usually occurs within 5 minutes of morphine
administration, and suggests that we were not able to sim-
ulate exactly the human environment where histamine
release occurs. It is likely that although the sulfite radical
is formed rapidly in vitro, it may take some time for its
effects to become evident [32].
Metabolic activation of sodium bisulfite may occur
through a variety of mechanisms. We investigated a
number of enzyme systems and our final model used
prostaglandin H synthetase. Other enzyme systems
(horseradish peroxidase/ hydrogen peroxide and hypox-
anthine/ xanthine oxidase) did release histamine in our
model (results not shown), but they produced excess
background interference in the chromatograms and made
identification of peaks difficult. Activation of sulfite fol-
lowing morphine administration may not occur through
this mechanism, however, and is another possible flaw in
our aim to construct a model similar to the one that exists
in vivo.
Morphine has been shown to cause significant histamine
release in vivo, but it has not been investigated whether
sulfite, in the form of the sulfite radical, is the cause of this
release. Our study finds that sulfite in sulfite-containing
morphine solutions, at clinically attained concentrations,
is not responsible for histamine release in in vitro experi-
ments of the mast cell line HMC-1, but this does not pre-
clude the fact that sulfite may lead to marked elevation in
histamine levels in vivo. The release of a significant
amount of histamine with either sulfite or morphine at
concentrations higher than those seen clinically suggests
that both substances may be responsible for histamine
release from mast cells. Further clinical research studies
need to be performed to examine this possibility.
Conclusions
Our study finds that the sulfite in sulfite-containing mor-
phine solutions, at concentrations seen clinically is not
responsible for histamine release in in vitro experiments of
the mast cell line, HMC-1, but this does not preclude the
fact that sulfite may lead to marked elevation in histamine
levels in vivo. Our experiments suggest that at high concen-
trations, both morphine and sulfite are responsible for
histamine release from mast cells. Further in vivo research
needs to be performed to examine this possibility.
Methods
Preparation of HMC-1 cells
Human leukemic mast cells, HMC-1 [33] were kindly pro-
vided by J. Butterfield, Rochester, Minnesota. This cell line
shows many characteristics of immature mast cells. They
have been shown to release histamine following stimula-
tion [28-30] Cells were carried in 75 cm2 vented tissue cul-
ture flasks (BD Falcon, Franklin Lakes, NJ) containing
Iscoves modified Dulbecco's medium (Sigma, St.Louis,
MO) with 10% iron-supplemented calf serum (Hyclone,
Logan, Utah) and monothioglycerol 1.2 mM (Sigma,
St.Louis, MO). Incubations were conducted in a humidi-
fied atmosphere at 5% CO2 and 37°C. Cells were passed
weekly and fed only when necessary (evidence of color
change in media).
To pass cells, the cell suspension was placed in a 50 ml
polypropylene centrifuge tube (BD Falcon, Franklin
Lakes, NJ) and centrifuged at 250 × g at 4°C for 10 min-
utes. The culture medium was discarded and the cells wereBMC Pharmacology 2004, 4:21 http://www.biomedcentral.com/1471-2210/4/21
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re-suspended in fresh medium. Cell density was main-
tained at 500,000 cells/ml.
Chemicals
Reagent grade O-phthaldialdehyde (OPA), mercaptoetha-
nol, dihydrogen sodium phosphate, disodium EDTA,
sodium bisulfite, morphine sulfate, hydrogen peroxide,
xanthine oxidase, boric acid and phosphate buffered
saline (PBS) were purchased from Sigma (St.Louis, MO,
USA). Methanol (HPLC grade), acetonitrile (HPLC grade)
and sodium hydroxide were from Fisher Scientific
(Hampton, NH). Phosphate buffered saline (PBS) pH 7.4,
contained 120 mmol/L NaCl, 2.7 mmol/L KCl and 10
mmol/L phosphate. Horseradish peroxidase was pur-
chased from Cooper Biomedical. Prostaglandin H syn-
thetase was purchased from Calbiochem (Darmstadt,
Germany).
Determination of histamine release
Mast cell suspensions, containing approximately 500,000
mast cells were, aliquoted into 1 ml samples. These were
rinsed 4 times with 4 ml of PBS, pH 7.4. Cells were then
re-suspended in 1 ml PBS. Reaction mixtures were supple-
mented with morphine, sulfite and prostaglandin H syn-
thase at this stage according to experimental design,
unless otherwise specified. Reaction mixtures were incu-
bated for 60 minutes in a water bath at 37°C. Reactions
were stopped by centrifugation at 250 × g for 4 minutes at
4°C and placed on ice. Then 200µl of the supernatant was
collected and dried under nitrogen at 40°C.
Histamine in the supernatant was measured using derivi-
tization with OPA and mercaptoethanol (ME) as
described [34]. Dried samples were re-dissolved in 100µl
of derivitisation buffer (0.4 M boric acid adjusted to pH
9.5 with 1 M sodium hydroxide) and then derivitized with
20 µL of a freshly made 1:1 mixture of OPA (3.8 mM in
methanol) and ME (2.5 ml/L in methanol) and analyzed
within 30 minutes. The derivitized samples were used for
chromatography.
The response of HMC-1 cells to the stimulant calcium
ionophore was investigated to assess the releasability of
HMC-1 cells. 0.25µg/ml calcium ionophore was added to
mast cell suspensions. Reaction mixtures were incubated
and analyzed as above.
Recovery of total histamine from cells
To extract the remaining histamine from the original sam-
ple, the mast cell pellet in suspension was frozen and
thawed 3 times. It was then centrifuged at 250 × g for 4
minutes and 200µl of the supernatant was dried under
nitrogen as described previously. Samples were re-dis-
solved, derivitized and analyzed as above. Histamine
release during morphine incubations was expressed as a
percentage of total histamine release.
Chromatography system
Histamine was measured by high-performance liquid
chromatography using a Varian model 5500 chromato-
graph. The mobile phase was 0.1 M dihydrogen sodium
phosphate and 1 mM disodium EDTA with 16% metha-
nol and 14% acetonitrile adjusted to pH 6.4. The flow rate
was 0.8 ml/minute.
Separations were performed using a 15 cm × 4.6 mm, Ace
5 C18 reversed-phase cartridge column (Advanced Chro-
matography technologies, UK). A Zorbax C8 guard col-
umn with a 5 micron, 4.6 × 12.5 mm analytical guard-
column cartridge (Agilent technologies, Palo Alto, CA)
was used. Fluorescence detection was used with the fluor-
imeter (Varian 9070) set at an excitation of 348 nm and
an emission of 444 nm (determined by running individ-
ual excitation and emission spectra on the fluorometer).
Chromatographic conditions involved the use of a mobile
phase gradient to optimize peak separation. A linear gra-
dient starting at 90% mobile phase, 10% acetonitrile and
ending at 80% mobile phase, 20% acetonitrile took place
over 20 minutes. The column was washed by increasing
the acetonitrile to 30% by 22 minutes and by 23 minutes
the proportions were returned to the original values. The
length of each run was 30 minutes.
Data analysis
Values are expressed as a mean +/- SD of 3 experiments.
One-way analysis of variance was used to determine the
significance of the difference between groups. Results
were considered significantly different when p < 0.05.
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